Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...
TD Cowen Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
What is HC Wainwright’s Estimate for SRPT FY2024 Earnings?
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
Temporary Revenue Surge and Market Penetration Concerns Lead to Sell Rating for Sarepta Therapeutics
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
Assenagon Asset Management S.A. Has $16.11 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
Seeking Alpha4d
SRPT Sarepta Therapeutics, Inc.
View Sarepta Therapeutics, Inc. (SRPT) current and estimated P/E ratio data provided by Seeking Alpha.
Nasdaq1mon
SRPT Factor-Based Stock Analysis
Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our P/B Growth Investor model based on the published ...